{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:50:44Z","timestamp":1759481444194,"version":"3.38.0"},"reference-count":64,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.nephro.2014.03.003","type":"journal-article","created":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T21:01:46Z","timestamp":1406754106000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Polykystose r\u00e9nale autosomique dominante\u00a0: le traitement est-il pour demain\u00a0?"],"prefix":"10.1684","volume":"10","author":[{"given":"Emilie","family":"Cornec-Le Gall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2014.03.003_bib0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1399-0004.1989.tb03204.x","article-title":"Autosomal dominant polycystic kidney disease in the 1980's","volume":"36","author":"Dalgaard","year":"1989","journal-title":"Clin Genet"},{"key":"10.1016\/j.nephro.2014.03.003_bib0010","first-page":"123","article-title":"Epidemiologic data, clinical and prognostic features of autosomal dominant polycystic kidney disease in a French region","volume":"17","author":"Simon","year":"1996","journal-title":"Nephrologie"},{"issue":"Suppl. 1","key":"10.1016\/j.nephro.2014.03.003_bib0015","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1769-7255(13)70037-3","article-title":"Registre rein. [The network]","volume":"9","author":"Couchoud","year":"2013","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2014.03.003_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2014.03.003_bib0025","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0030","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/jmg.30.7.583","article-title":"Childhood onset autosomal dominant polycystic kidney disease in sibs: clinical picture and recurrence risk. German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie)","volume":"30","author":"Zerres","year":"1993","journal-title":"J Med Genet"},{"key":"10.1016\/j.nephro.2014.03.003_bib0035","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1681\/ASN.V5122048","article-title":"Causes of death in autosomal dominant polycystic kidney disease","volume":"5","author":"Fick","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2000.17619","article-title":"Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients","volume":"36","author":"Torra","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.03.003_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.nephro.2014.03.003_bib0050","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1681\/ASN.2005060645","article-title":"Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells","volume":"17","author":"Yamaguchi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0055","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.03.003_bib0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1523-1755.1998.00990.x","article-title":"Regulation of cAMP production in initial and terminal inner medullary collecting ducts","volume":"54","author":"Yasuda","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.03.003_bib0065","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nephro.2014.03.003_bib0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.03.003_bib0075","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.1073\/pnas.93.19.10206","article-title":"Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells","volume":"93","author":"Brill","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nephro.2014.03.003_bib0080","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0085","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00424-002-0880-3","article-title":"Basolateral chloride transporters in autosomal dominant polycystic kidney disease","volume":"444","author":"Lebeau","year":"2002","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.nephro.2014.03.003_bib0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2011.87","article-title":"WNT\/\u03b2-catenin signaling in polycystic kidney disease","volume":"80","author":"Wuebken","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.03.003_bib0095","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/ng1552","article-title":"Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways","volume":"37","author":"Simons","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.nephro.2014.03.003_bib0100","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1073\/pnas.1103816108","article-title":"Polycystin-1 regulates STAT activity by a dual mechanism","volume":"108","author":"Talbot","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nephro.2014.03.003_bib0105","first-page":"e23650","article-title":"Regulation of STATs by polycystin-1 and their role in polycystic kidney disease","volume":"2","author":"Weimbs","year":"2013","journal-title":"JAKSTAT"},{"key":"10.1016\/j.nephro.2014.03.003_bib0110","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1681\/ASN.2008080882","article-title":"Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease","volume":"20","author":"Schrier","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.03.003_bib0125","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2014.03.003_bib0130","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2014.03.003_bib0135","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0140","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0145","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2014.03.003_bib0150","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated rapamycin slows progression of polycystic kidney disease","volume":"23","author":"Shillingford","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0155","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0165","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.nephro.2014.03.003_bib0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.nephro.2014.03.003_bib0175","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0180","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.03.003_bib0185","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2014.03.003_bib0190","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: a pilot study","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0200","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of long acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2014.03.003_bib0205","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0700499104","article-title":"Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease","volume":"104","author":"Leuenroth","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nephro.2014.03.003_bib0210","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1681\/ASN.2008030259","article-title":"Triptolide reduces cystogenesis in a model of ADPKD","volume":"19","author":"Leuenroth","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0215","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/ndt\/gfp777","article-title":"Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD","volume":"25","author":"Leuenroth","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.03.003_bib0220","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nephro.2014.03.003_bib0225","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.nephro.2014.03.003_bib0230","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1535-7163.MCT-11-0497","article-title":"Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models","volume":"10","author":"Cheong","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nephro.2014.03.003_bib0235","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","article-title":"Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model","volume":"300","author":"Leonhard","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0240","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature05348","article-title":"Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine","volume":"444","author":"Bukanov","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.nephro.2014.03.003_bib0245","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.4161\/cc.22375","article-title":"CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD","volume":"11","author":"Bukanov","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.nephro.2014.03.003_bib0250","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1093\/ndt\/gfq545","article-title":"Lipids and renal cystic disease","volume":"25","author":"Schrier","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.03.003_bib0255","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.nephro.2014.03.003_bib0260","doi-asserted-by":"crossref","first-page":"F944","DOI":"10.1152\/ajprenal.00387.2010","article-title":"Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells","volume":"299","author":"Yamaguchi","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0265","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2014.03.003_bib0270","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: a review","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.nephro.2014.03.003_bib0275","doi-asserted-by":"crossref","first-page":"21819","DOI":"10.1073\/pnas.0911987106","article-title":"Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models","volume":"106","author":"Cao","year":"2009","journal-title":"PNAS"},{"key":"10.1016\/j.nephro.2014.03.003_bib0280","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ajpath.2011.04.036","article-title":"Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients","volume":"179","author":"Caroli","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0285","doi-asserted-by":"crossref","first-page":"e32533","DOI":"10.1371\/journal.pone.0032533","article-title":"Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study","volume":"7","author":"Ruggenenti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2014.03.003_bib0290","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","article-title":"Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease","volume":"8","author":"Johnson","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0295","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0300","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/humu.22103","article-title":"Autosomal dominant polycystic kidney disease: Comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients","volume":"33","author":"Audrezet","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nephro.2014.03.003_bib0305","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1681\/ASN.2011101032","article-title":"Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing","volume":"23","author":"Rossetti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0310","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0315","doi-asserted-by":"crossref","first-page":"F1166","DOI":"10.1152\/ajprenal.00196.2007","article-title":"Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL","volume":"293","author":"Mutig","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nephro.2014.03.003_bib0320","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725514000959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725514000959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2014.03.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:01:46Z","timestamp":1741186906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725514000959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1769725514000959"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2014.03.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polykystose r\u00e9nale autosomique dominante\u00a0: le traitement est-il pour demain\u00a0?","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2014.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Association Soci\u00e9t\u00e9 de n\u00e9phrologie. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}